Q3-MEDICAL
Q3 Medical Devices Limited (“Q3 Medical”) based in Dublin, Ireland, announced today that it has entered into a distribution agreement with Medtronic plc for ARCHIMEDES, the first to market fully biodegradable biliary and pancreatic stent designed as an alternative to traditional plastic stents.
Medtronic’s Gastrointestinal and Hepatology business, which is part of the Minimally Invasive Therapies Group and Q3 Medical agreed to a six-year, exclusive agreement to distribute ARCHIMEDES biodegradable stent in western EU, US, and Japan; with rights to other regions. Q3 Medical will continue to expand its presence in South East Asia, Latin America, Eastern Europe, and the Middle East.
Typically, biliary and pancreatic duct stents are made of plastic or metal, however the ARCHIMEDES stent is made of a combination of dissolving materials permitting different rates of degradation depending on the patient need. Use of degrading materials in a stent, decreases reinterventions that are common with current stents and allows the potential for eliminating a stent removal procedure which is almost always done for plastic and metal stents currently. ARCHIMEDES has CE Mark.
Eric Mangiardi, President & CEO of Q3 Medical stated, “We are excited and fortunate to have partnered with a world leading medical device organization like Medtronic. Entering into this agreement is a major step toward our goal of becoming the world leading developer of biodegradable implants. Mangiardi further stated; “The promise of ARCHIMEDES is based in its potential to eliminate the second removal procedure required for traditional plastic stents, which could reduce billions of expenses from the global healthcare system while improving patient care.”
About Q3 Medical Devices
Q3 Medical Devices Limited is an Irish based holding company focused on the acquisition of novel medical device businesses with annual revenues up to EUR 10 Million. The holding company, through its expanding operations in Winsen, Germany (QualiMed Innovative Medizinprodukte GmbH, AMG International GmbH); Shanghai, China (Q-San); and Charlotte, N.C. (QualiMed-USA) is focused on the development, manufacturing, and distribution of minimally invasive devices for the treatment of patients with cardiology, peripheral vascular, and non-vascular diseases.
The wholly owned companies are focused on the continued global development and commercialization of their Core, Micro Invasive, Biodegradable, & Drug Delivery Technologies. The Company’s products are now sold in over 50 countries worldwide through its OEM, Private Label, and Own Brand Networks. Q3 Medical, through its wholly owned subsidiaries is focused on three key Verticals in which it will compete; Biodegradable Implants, Micro Invasive Technologies, and Drug Delivery Platforms.
Q3 Medical Devices Limited was formed by a global group of entrepreneurs, manufactures, distributors, industry doctors, and investors focused on the development and acquisition of medical device businesses. The company is focused on Creating Value By Helping People.
For further information, please visit http://www.q3medical.com/ .
“CREATING VALUE BY HELPING PEOPLE”
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514006144/en/
Contact:
Eric Mangiardi President & CEO Q3 Medical Devices Limited +353867827296 (Ireland) emangiardi@q3medical.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Symrise and Aplantex Confirm an Agreement to Establish a Partnership14.10.2025 12:00:00 CEST | Press release
Symrise AG ("Symrise") and Aplantex Bio ("Aplantex") agree on a partnership covering new technologies for accessing plant-based molecules as raw material once the molecules of interest have been developed and produced by Aplantex. "We are intrigued by the potential of Aplantex’s innovative green biotechnology process to help us in securing potential access to hard-to-source plant-based molecules in the context of the significant impacts of climate change," underlines Dr. Jakob Ley, director of Biobased Ingredients Research at Symrise. Aplantex has been, since 2024, diligently involved in the research & development work to produce the initial molecule of interest requested by Symrise. "Having already validated our process with the production of Apigenin, Orientin, Vitexin, and Luteolin, four molecules recognized for their antioxidant, anti-inflammatory, antimicrobial, and anti-aging properties, we were able to reach several milestones of Symrise’s validation protocol in record time. We
Europe’s Tech Services Market Slows in Q3, Despite Strong AI-Driven Cloud Demand: ISG Index™14.10.2025 10:00:00 CEST | Press release
Combined market up 5% in Q2, driven by 41% growth in cloud servicesManaged services slumps 25%, as companies remain cautious in the face of macro challenges Europe’s market for technology services and software slowed in the third quarter despite continuing strong demand for AI, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows third-quarter ACV for the combined market (both managed services and cloud-based as-a-service) rose 5 percent, to US $9.7 billion. Although the market has grown for seven consecutive quarters, averaging 14 percent quarterly growth during that span, the rate of growth in the third quarter was the lowest since the second quarter last year. “The market in Europe continues to be buoyed by strong, double-digit growth in cl
euNetworks Delivers New Fully Diverse Long Haul Network Route, Enabling Two Short Paths Connecting Frankfurt to Marseille and Milan14.10.2025 10:00:00 CEST | Press release
The shorter routes from Frankfurt to Marseille and Milan significantly reduce network latency for customers requiring diverse connectivity. The network enhances route diversity in the region, delivering new fibre routing for companies entering Europe via Marseille. euNetworks Group Limited (“euNetworks”), a European critical bandwidth infrastructure company, has today announced the completion of a new long haul fibre network route between Frankfurt and Zurich. This new network enables two short diverse paths between the many submarine cable landings along the Mediterranean coast, and the major data centre market of Frankfurt. The new route completes one of two fully diverse euNetworks long haul routes, with the option to either go via Milan and Zurich or via Marseille, Lyon and Geneva. euNetworks undertook this network investment to increase diversity options for its customers, enabling them to avoid points of failure where routes converge and cross, or otherwise take a long detour via
Hamad International Airport's Senior Operations Manager appointed as CEO of Ancona International Airport14.10.2025 09:00:00 CEST | Press release
Ancona International Airport (“AIA”), a Njord Partners portfolio company, is pleased to announce the appointment of Giorgio Buffa as its new Chief Executive Officer, effective 13 October 2025. Giorgio Buffa joins Ancona from Doha’s Hamad International Airport, where he was the Senior Operations Manager. He brings over 20 years of dedicated experience in the airport and airline industries, having spent his entire career in aviation. He is recognised for driving operational excellence and pioneering sustainable development at Hamad International Airport, which has, for multiple years, been named the "World's Best Airport" by Skytrax, setting new standards in the airport sector. For the past nine years, he has been instrumental in overseeing key operational functions and successfully navigated the COVID-19 period as well as major events such as the FIFA World Cup. Formerly a pilot with Alitalia and Air One, Giorgio has held various senior leadership roles in airport operations, including
PPG introduces PPG MIX‘N’SHAKE automated stirring technology for body shops14.10.2025 08:30:00 CEST | Press release
System improves productivity, reduces waste, enhances color accuracy PPG (NYSE: PPG) today announced the introduction of PPG MIX‘N’SHAKE™ automated stirring technology designed to eliminate traditional manual stirring methods in the automotive refinish industry. The system, which is available globally, improves paint mix consistency, reduces consumable waste and saves time for painters and body shops. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013065453/en/ PPG MIX’N’SHAKE™ automated stirring technology replaces manual stirring processes to ensure a homogenized paint mix, complete color accuracy, and a better workplace. The PPG Mix‘n’Shake system will debut at the EQUIP AUTO trade show in Paris taking place Oct. 14-18. PPG will also showcase its PPG LINQ™ digital ecosystem, which is a finalist for the prestigious EQUIP AUTO Innovation Award. Because the PPG Mix‘n’Shake system eliminates manual stirring, it ensures con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom